6.
Ho Y, Shan L, Hosmane N, Wang J, Laskey S, Rosenbloom D
. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013; 155(3):540-51.
PMC: 3896327.
DOI: 10.1016/j.cell.2013.09.020.
View
7.
Donahue D, Kuhl B, Sloan R, Wainberg M
. The viral protein Tat can inhibit the establishment of HIV-1 latency. J Virol. 2012; 86(6):3253-63.
PMC: 3302319.
DOI: 10.1128/JVI.06648-11.
View
8.
Donahue D, Bastarache S, Sloan R, Wainberg M
. Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses. J Virol. 2013; 87(17):9620-32.
PMC: 3754111.
DOI: 10.1128/JVI.01165-13.
View
9.
Emiliani S, Fischle W, Ott M, Van Lint C, Amella C, Verdin E
. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol. 1998; 72(2):1666-70.
PMC: 124653.
DOI: 10.1128/JVI.72.2.1666-1670.1998.
View
10.
Zaikos T, Terry V, Sebastian Kettinger N, Lubow J, Painter M, Virgilio M
. Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients. Cell Rep. 2018; 25(13):3759-3773.e9.
DOI: 10.1016/j.celrep.2018.11.104.
View
11.
Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias M, Martin M, Barbas C
. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. 2016; 30(9):1385-92.
DOI: 10.1097/QAD.0000000000001064.
View
12.
Levy D, Refaeli Y, Weiner D
. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol. 1995; 69(2):1243-52.
PMC: 188697.
DOI: 10.1128/JVI.69.2.1243-1252.1995.
View
13.
Hottiger M, Nabel G
. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol. 1998; 72(10):8252-6.
PMC: 110181.
DOI: 10.1128/JVI.72.10.8252-8256.1998.
View
14.
Tang X, Lu H, Dooner M, Chapman S, Quesenberry P, Ramratnam B
. Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes. JCI Insight. 2018; 3(7).
PMC: 5928859.
DOI: 10.1172/jci.insight.95676.
View
15.
Collman R, Balliet J, Gregory S, Friedman H, Kolson D, NATHANSON N
. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol. 1992; 66(12):7517-21.
PMC: 240461.
DOI: 10.1128/JVI.66.12.7517-7521.1992.
View
16.
Atindaana E, Kissi-Twum A, Emery S, Burnett C, Pitcher J, Visser M
. Bimodal Expression Patterns, and Not Viral Burst Sizes, Predict the Effects of Vpr on HIV-1 Proviral Populations in Jurkat Cells. mBio. 2022; 13(2):e0374821.
PMC: 9040753.
DOI: 10.1128/mbio.03748-21.
View
17.
Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner F, Cron R
. Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol. 2009; 83(7):3078-93.
PMC: 2655589.
DOI: 10.1128/JVI.02058-08.
View
18.
Schrager J, Marsh J
. HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci U S A. 1999; 96(14):8167-72.
PMC: 22206.
DOI: 10.1073/pnas.96.14.8167.
View
19.
Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C
. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5.
DOI: 10.1126/science.278.5341.1291.
View
20.
Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M
. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7.
PMC: 24285.
DOI: 10.1073/pnas.94.24.13193.
View